Natco Pharma Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injection".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natco Pharma, along with Lupin Limited, has received approval from the U.S. FDA for Eribulin Mesylate Injection, a generic injectable used in the treatment of metastatic breast cancer. This approval allows both companies to manufacture and market the product in the U.S. market. Eribulin Mesylate is a complex injectable generic with limited competition, making it a high-value opportunity. The partnership with Lupin gives Natco access to established U.S. distribution channels. This adds to Natco's growing portfolio of approved complex generics in the U.S.
Positive for shareholders — the approval strengthens Natco's U.S. product pipeline and could boost future revenues, though actual financial impact will depend on launch timelines, pricing, and market share captured alongside Lupin.